Related references
Note: Only part of the references are listed.BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
L. Robertson et al.
BRITISH JOURNAL OF CANCER (2012)
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
Anne-Renee Hartman et al.
CANCER (2012)
Relative contributions of BRCA1 and BRCA2 mutations to triple-negative breast cancer in Ashkenazi Women
E. Comen et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors
Janice S. Kwon et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
Mark E. Robson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
S. R. Young et al.
BMC CANCER (2009)
BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer
Michael J. Hall et al.
CANCER (2009)
Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
Yu Chuan Tai et al.
BREAST CANCER RESEARCH (2008)
American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility
SS Bruinooge
JOURNAL OF CLINICAL ONCOLOGY (2003)
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
DA Berry et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
